@article {784,
	title = {Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats},
	journal = {Canadian Journal of Physiology and Pharmacology},
	volume = {81},
	number = {11},
	year = {2003},
	note = {ISI Document Delivery No.: 749AHTimes Cited: 3Cited Reference Count: 47},
	month = {Nov},
	pages = {1049-1055},
	type = {Article},
	abstract = {The aim of this study was to determine if there was a synergistic or additive effect of a thiazolidinedione derivative (rosiglitazone (ROS)) and a vanadium compound (bis(ethylmaltolato)oxovanadium(IV) (BEOV)) on plasma glucose and insulin levels following chronic oral administration to Zucker diabetic fatty (ZDF) rats. Whole-blood vanadium levels were determined at time 0 and at days 1, 6, and 18. The doses of BEOV (0.1 mmol/kg) and ROS (2.8 mumol/kg) were selected to produce a glucose-lowering effect in 30\% (ED30) of animals. Both drugs were administered daily by oral gavage as suspensions in 1\% carboxymethylcellulose (CMC) in a volume of 2.5 mL/kg. The total volume administered to all rats was 5 mL/(kg-day). The combination of BEOV and ROS was effective in lowering plasma glucose levels to <9 mmol/L in 60\% of fatty animals as compared with 30\% for BEOV and 10\% for ROS alone. The age-dependent decrease in plasma insulin levels associated with \&beta;-cell failure in the ZDF rats did not occur in the BEOV-treated fatty groups. There was no effect of any treatment on body weight; however, there was a significant reduction in both food and fluid intake in fatty groups treated with BEOV. There were no overt signs of toxicity and no mortality in this study. Both BEOV and ROS were effective in lowering plasma glucose levels, as stated above, and there was at least an additive effect when BEOV and ROS were used in combination.},
	keywords = {ACTIVATED-RECEPTOR-GAMMA, bis(ethylmaltolato)oxovanadium(IV), diabetes, GLUT4, IN-VIVO, INSULIN SENSITIVITY, ORAL VANADYL, PHOSPHOENOLPYRUVATE-CARBOXYKINASE, RATS, rosigitazone, SKELETAL-MUSCLE, STREPTOZOTOCIN-DIABETIC RATS, TRANSLOCATION, VANADYL SULFATE, ZDF rats, ZUCKER FATTY},
	isbn = {0008-4212},
	url = {<Go to ISI>://000186896100007},
	author = {Yuen, V. G. and Bhanot, S. and Battell, M. L. and Orvig, Chris and McNeill, J. H.}
}
@article {4683,
	title = {Vanadium compounds as insulin mimics},
	journal = {Chemical Reviews},
	volume = {99},
	number = {9},
	year = {1999},
	note = {ISI Document Delivery No.: 235XUTimes Cited: 376Cited Reference Count: 124},
	month = {Sep},
	pages = {2561-2571},
	type = {Review},
	keywords = {AGENT BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, BIOLOGICAL-SYSTEMS, COMPOUNDS, GLUCOSE-METABOLISM, IN-VIVO, MIMETIC AGENT, OXIDATIVE STRESS, PEROXOVANADIUM, PHOSPHOTYROSINE PHOSPHATASE INHIBITORS, STREPTOZOTOCIN-DIABETIC RATS, TYROSINE PHOSPHORYLATION},
	isbn = {0009-2665},
	url = {<Go to ISI>://000082569800015},
	author = {Thompson, K. H. and McNeill, J. H. and Orvig, Chris}
}
@inbook {3468,
	title = {VANADIUM COMPOUNDS AS INSULIN MIMICS},
	booktitle = {Metal Ions in Biological Systems, Vol 31},
	series = {Metal Ions in Biological Systems},
	volume = {31},
	year = {1995},
	note = {ISI Document Delivery No.: BD60ZTimes Cited: 106Cited Reference Count: 126Review270 MADISON AVE, NEW YORK, NY 10016},
	pages = {575-594},
	publisher = {Marcel Dekker},
	organization = {Marcel Dekker},
	address = {New York},
	keywords = {AMINO-ACID, ANTIOXIDANT STATUS, BLOOD-GLUCOSE, GLYCOGEN-SYNTHASE, INSULINOMIMETIC AGENTS, LEVELS, ORAL VANADYL, RECEPTOR TYROSINE KINASE, SKELETAL-MUSCLE, STREPTOZOTOCIN-DIABETIC RATS, VANADATE TREATMENT},
	isbn = {0161-5149},
	url = {<Go to ISI>://A1995BD60Z00017},
	author = {Orvig, Chris and Thompson, K. H. and Battell, M. and McNeill, J. H.}
}
